These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31505986)

  • 41. A comparative study of matched pair designs with two binary endpoints.
    Jiang Y; Xu J
    Stat Methods Med Res; 2017 Dec; 26(6):2526-2542. PubMed ID: 26294329
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD
    Stat Methods Med Res; 2019 Jun; 28(6):1852-1878. PubMed ID: 29869564
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sample size determination and re-estimation for matched pair designs with multiple binary endpoints.
    Xu J; Yu M
    Biom J; 2013 May; 55(3):430-43. PubMed ID: 23553605
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
    Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M
    Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Endpoint Bioequivalence Studies Are Not Sensitive: A Perspective From Generic Drugs.
    Novakovic J; Szirtes J; Fields A; Tsang YC
    Clin Pharmacol Ther; 2019 Feb; 105(2):295-297. PubMed ID: 30456787
    [No Abstract]   [Full Text] [Related]  

  • 47. Power and sample size determination in clinical trials with multiple primary continuous correlated endpoints.
    Lafaye de Micheaux P; Liquet B; Marque S; Riou J
    J Biopharm Stat; 2014; 24(2):378-97. PubMed ID: 24605975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of the upper sample size limit in two-stage bioequivalence designs.
    Karalis V
    Int J Pharm; 2013 Nov; 456(1):87-94. PubMed ID: 23954235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study.
    Jones B; Li B; Bagger M; Goodyear A; Ludwig I
    Pharm Stat; 2022 Nov; 21(6):1357-1365. PubMed ID: 35604539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Testing for qualitative heterogeneity: An application to composite endpoints in survival analysis.
    Oulhaj A; El Ghouch A; Holman RR
    Stat Methods Med Res; 2019 Jan; 28(1):151-169. PubMed ID: 28670972
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sample size determination in bioequivalence studies using statistical assurance.
    Ring A; Lang B; Kazaroho C; Labes D; Schall R; Schütz H
    Br J Clin Pharmacol; 2019 Oct; 85(10):2369-2377. PubMed ID: 31276603
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sample sizes for clinical trials with normal data.
    Julious SA
    Stat Med; 2004 Jun; 23(12):1921-86. PubMed ID: 15195324
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sample size re-estimation in a breast cancer trial.
    Hade EM; Jarjoura D; Lai Wei
    Clin Trials; 2010 Jun; 7(3):219-26. PubMed ID: 20392786
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials.
    Hindiyeh NA; Kellerman DJ; Schmidt PC
    Headache; 2019 May; 59(5):819-824. PubMed ID: 30953576
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Endpoint Bioequivalence Studies Are Needed: A Perspective From Brand Drugs.
    Krishna R; Kesisoglou F
    Clin Pharmacol Ther; 2019 Feb; 105(2):298-300. PubMed ID: 30456848
    [No Abstract]   [Full Text] [Related]  

  • 56. Pivotal Bioequivalence Study of Clopacin®, a Generic Formulation of Clopidogrel 75 mg Film-Coated Tablets.
    McGregor GP
    Adv Ther; 2016 Feb; 33(2):186-98. PubMed ID: 26825365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Re-estimating the sample size of an on-going blinded trial based on the method of randomization block sums.
    Ganju J; Xing B
    Stat Med; 2009 Jan; 28(1):24-38. PubMed ID: 18837073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A post hoc evaluation of a sample size re-estimation in the Secondary Prevention of Small Subcortical Strokes study.
    McClure LA; Szychowski JM; Benavente O; Hart RG; Coffey CS
    Clin Trials; 2016 Oct; 13(5):537-44. PubMed ID: 27094488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blinded sample size reassessment in non-inferiority and equivalence trials.
    Friede T; Kieser M
    Stat Med; 2003 Mar; 22(6):995-1007. PubMed ID: 12627414
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measurement error in continuous endpoints in randomised trials: Problems and solutions.
    Nab L; Groenwold RHH; Welsing PMJ; van Smeden M
    Stat Med; 2019 Nov; 38(27):5182-5196. PubMed ID: 31478240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.